Scolaris Content Display Scolaris Content Display

Contenido relacionado

Ir a:

Revisiones y protocolos relacionados

Topics

Temas

Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.
Figuras y tablas -
Figure 1

Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Forest plot of comparison: 1 SULPIRIDE AUGMENTATION OF CLOZAPINE vs CLOZAPINE, outcome: 1.20 SENSITIVITY ‐ Global/mental state: No clinically important response ‐ short term.
Figuras y tablas -
Figure 2

Forest plot of comparison: 1 SULPIRIDE AUGMENTATION OF CLOZAPINE vs CLOZAPINE, outcome: 1.20 SENSITIVITY ‐ Global/mental state: No clinically important response ‐ short term.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Methodological quality summary: review authors' judgements about each methodological quality item for each included study.
Figuras y tablas -
Figure 3

Methodological quality summary: review authors' judgements about each methodological quality item for each included study.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs ANY ANTIPSYCHOTIC DRUG, Outcome 1 Global state: 1. No clinically important response.
Figuras y tablas -
Analysis 1.1

Comparison 1 SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs ANY ANTIPSYCHOTIC DRUG, Outcome 1 Global state: 1. No clinically important response.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs ANY ANTIPSYCHOTIC DRUG, Outcome 2 Global state: 2. Relapse.
Figuras y tablas -
Analysis 1.2

Comparison 1 SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs ANY ANTIPSYCHOTIC DRUG, Outcome 2 Global state: 2. Relapse.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs ANY ANTIPSYCHOTIC DRUG, Outcome 3 Mental state: 1a. General ‐ No clinical important improvement.
Figuras y tablas -
Analysis 1.3

Comparison 1 SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs ANY ANTIPSYCHOTIC DRUG, Outcome 3 Mental state: 1a. General ‐ No clinical important improvement.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs ANY ANTIPSYCHOTIC DRUG, Outcome 4 Mental state: 1b. General ‐ Average endpoint scores.
Figuras y tablas -
Analysis 1.4

Comparison 1 SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs ANY ANTIPSYCHOTIC DRUG, Outcome 4 Mental state: 1b. General ‐ Average endpoint scores.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs ANY ANTIPSYCHOTIC DRUG, Outcome 5 Mental state: 1c. General ‐ Average change in endpoint scores.
Figuras y tablas -
Analysis 1.5

Comparison 1 SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs ANY ANTIPSYCHOTIC DRUG, Outcome 5 Mental state: 1c. General ‐ Average change in endpoint scores.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Study

Intervention

Mean

SD

N

Statistic

change in BPRS ‐ short term

Shiloh 1997

Sulpiride plus clozapine

Clozapine

‐8.7

‐2.3

8.3

6.2

16

12

P<0.05

endpoint SAPS plus SANS ‐ short term

Wang 1994

Sulpiride plus clozapine

Clozapine

3.16

4.91

1.78

2.91

36

34

endpoint SAPS plus SANS ‐ long term

Wang 1994

Sulpiride plus clozapine

Clozapine

4.02

6.77

2.10

3.15

36

34

Figuras y tablas -
Analysis 1.6

Comparison 1 SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs ANY ANTIPSYCHOTIC DRUG, Outcome 6 Mental state: 1d. General ‐ Average endpoint and average change in endpoint scores (skewed data).

Ir a la figura de la revisión

Comparison 1 SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs ANY ANTIPSYCHOTIC DRUG, Outcome 7 Mental state: 2a. Negative symptoms ‐ No clinical important improvement.
Figuras y tablas -
Analysis 1.7

Comparison 1 SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs ANY ANTIPSYCHOTIC DRUG, Outcome 7 Mental state: 2a. Negative symptoms ‐ No clinical important improvement.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs ANY ANTIPSYCHOTIC DRUG, Outcome 8 Mental state: 2b. Negative symptoms ‐ Average endpoint scores.
Figuras y tablas -
Analysis 1.8

Comparison 1 SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs ANY ANTIPSYCHOTIC DRUG, Outcome 8 Mental state: 2b. Negative symptoms ‐ Average endpoint scores.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Study

Intervention

Mean

SD

N

Statistic

change in endpoint SANS ‐ short term

Shiloh 1997

Sulpiride plus clozapine

Clozapine

‐8.3

‐1.5

10.8

4.4

16

12

P<0.05

endpoint SANS ‐ short term

Zhu 1999

Sulpiride plus clozapine

Clozapine

23.6

28.2

14.3

17.5

29

30

Figuras y tablas -
Analysis 1.9

Comparison 1 SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs ANY ANTIPSYCHOTIC DRUG, Outcome 9 Mental state: 2c. Negative symptoms ‐ Average endpoint and average change in endpoint scores (skewed data).

Ir a la figura de la revisión

Comparison 1 SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs ANY ANTIPSYCHOTIC DRUG, Outcome 10 Mental state: 3a. Positive symptoms ‐ No clinical important improvement.
Figuras y tablas -
Analysis 1.10

Comparison 1 SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs ANY ANTIPSYCHOTIC DRUG, Outcome 10 Mental state: 3a. Positive symptoms ‐ No clinical important improvement.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Study

Intervention

Mean

SD

N

Statistic

change in endpoint SAPS ‐ short term

Shiloh 1997

Sulpiride plus clozapine

Clozapine

‐6.4

‐0.6

7.1

7.6

16

12

P<0.05

Figuras y tablas -
Analysis 1.11

Comparison 1 SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs ANY ANTIPSYCHOTIC DRUG, Outcome 11 Mental state: 3b. Positive symptoms ‐ Average endpoint and average change in endpoint scores (skewed data).

Ir a la figura de la revisión

Study

Intervention

Mean

SD

N

Statistic

depression scores (HAMD) ‐ short term

Shiloh 1997

Sulpiride plus clozapine

Clozapine

‐2.7

‐0.7

5.8

3.1

16

12

Figuras y tablas -
Analysis 1.12

Comparison 1 SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs ANY ANTIPSYCHOTIC DRUG, Outcome 12 Mental state: 4. Emotional symptoms ‐ Average endpoint and average change in endpoint scores (skewed data).

Ir a la figura de la revisión

Study

Intervention

Mean

SD

N

Statistic

TESS ‐ average endpoint scores (high = poor)

Zhu 1999

Sulpiride plus clozapine

Clozapine

3.4

2.9

2.5

2.3

29

30

None reported

Figuras y tablas -
Analysis 1.13

Comparison 1 SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs ANY ANTIPSYCHOTIC DRUG, Outcome 13 Adverse effects ‐ general: short term (skewed data).

Ir a la figura de la revisión

Comparison 1 SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs ANY ANTIPSYCHOTIC DRUG, Outcome 14 Adverse effects ‐ specific: 1a. CNS ‐ short term.
Figuras y tablas -
Analysis 1.14

Comparison 1 SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs ANY ANTIPSYCHOTIC DRUG, Outcome 14 Adverse effects ‐ specific: 1a. CNS ‐ short term.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs ANY ANTIPSYCHOTIC DRUG, Outcome 15 Adverse effects ‐ specific: 2. Cardiovsacular system (short‐term).
Figuras y tablas -
Analysis 1.15

Comparison 1 SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs ANY ANTIPSYCHOTIC DRUG, Outcome 15 Adverse effects ‐ specific: 2. Cardiovsacular system (short‐term).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs ANY ANTIPSYCHOTIC DRUG, Outcome 16 Adverse effects ‐ specific: 3a. Endocrine system (short‐term).
Figuras y tablas -
Analysis 1.16

Comparison 1 SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs ANY ANTIPSYCHOTIC DRUG, Outcome 16 Adverse effects ‐ specific: 3a. Endocrine system (short‐term).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Study

Intervention

Mean

SD

N

Statistic

prolactin ‐ average endpoint serum level (men)

Shiloh 1997

Sulpiride plus clozapine

Clozapine

75.4

18.0

19.8

13.4

11

8

prolactin ‐ average endpoint serum level (women)

Shiloh 1997

Sulpiride plus clozapine

Clozapine

101.8

16.9

41.0

11.8

5

4

Figuras y tablas -
Analysis 1.17

Comparison 1 SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs ANY ANTIPSYCHOTIC DRUG, Outcome 17 Adverse effects ‐ specific: 3b. Endocrine system (short‐term, skewed data).

Ir a la figura de la revisión

Comparison 1 SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs ANY ANTIPSYCHOTIC DRUG, Outcome 18 Adverse effects ‐ specific: 4. Gastrointestinal system (short‐term).
Figuras y tablas -
Analysis 1.18

Comparison 1 SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs ANY ANTIPSYCHOTIC DRUG, Outcome 18 Adverse effects ‐ specific: 4. Gastrointestinal system (short‐term).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs ANY ANTIPSYCHOTIC DRUG, Outcome 19 Adverse effects ‐ specific: 5. Haematology.
Figuras y tablas -
Analysis 1.19

Comparison 1 SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs ANY ANTIPSYCHOTIC DRUG, Outcome 19 Adverse effects ‐ specific: 5. Haematology.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs ANY ANTIPSYCHOTIC DRUG, Outcome 20 SENSITIVITY ‐ Global/mental state: No clinically important response (short‐term).
Figuras y tablas -
Analysis 1.20

Comparison 1 SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs ANY ANTIPSYCHOTIC DRUG, Outcome 20 SENSITIVITY ‐ Global/mental state: No clinically important response (short‐term).

Ir a la figura de la revisiónAbrir en una pestaña nueva
Table 2. Suggested design for future study

Methods

Allocation: randomised, clearly described.
Blinding: double, tested.
Duration: 1 year.

Participants

Diagnosis: schizophrenia.
N=300.*
Age: adults.
Sex: both.
History: severely ill, no clear response to clozapine given continuously in adequate doses for at least 12 weeks.

Interventions

1. Sulpiride + clozapine: sulpiride dosage 600‐800 mg/day, clozapine dosage previously used dosage. N=150.

2. Clozapine: previously used dosage. N=150.

Outcomes

Death.
Adverse effects: list, including serum prolactin level, weight change, hypersalivation, blood dyscrasia.
Service outcomes: admitted, ready for discharge.
Social functioning: working, trouble with family, trouble with police.
Satisfaction with treatment: binary outcome, family, clinician and participant.
Healthy days.
Economic data.
Compliance: attending follow up, taking medication, blood testing.

Notes

* Powered to be able to identify a difference of ˜20% between groups for primary outcome with adequate degree of certainty.

Figuras y tablas -
Table 2. Suggested design for future study
Ir a la tabla de la revisión
Summary of findings for the main comparison. SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG compared to ANY ANTIPSYCHOTIC DRUG for schizophrenia

SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG compared to ANY ANTIPSYCHOTIC DRUG for schizophrenia

Patient or population: patients with schizophrenia
Settings:
Intervention: SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG
Comparison: ANY ANTIPSYCHOTIC DRUG

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No of Participants
(studies)

Quality of the evidence
(GRADE)

Comments

Assumed risk

Corresponding risk

ANY ANTIPSYCHOTIC DRUG

SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG

Global state: No clinically important response ‐ short term

Study population

RR 0.58
(0.3 to 1.09)

193
(3 studies)

⊕⊕⊝⊝
low1,2,3,4,5,6

22 per 100

13 per 100
(7 to 24)

Medium risk population

25 per 100

14 per 100
(8 to 27)

Specific adverse effects: 1a. CNS ‐ short term ‐ movement disorder ‐ extrapyramidal effects

Study population

RR 48.24
(3.05 to 762.56)

70
(1 study)

⊕⊝⊝⊝
very low1,2,3,5,6,7,8

0 per 100

0 per 100
(0 to 0)

Medium risk population

0 per 100

0 per 100
(0 to 0)

Specific adverse effects: 3a. Endocrine system ‐ short term ‐ weight gain

Study population

RR 0.3
(0.09 to 0.99)

64
(1 study)

⊕⊕⊝⊝
low1,2,5,6

31 per 100

9 per 100
(3 to 31)

Medium risk population

31 per 100

9 per 100
(3 to 31)

Specific adverse effects: 4. Gastrointestinal system ‐ short term ‐ salavation ‐ too much

Study population

RR 0.49
(0.29 to 0.83)

162
(3 studies)

⊕⊕⊝⊝
low1,2,3,5,6,9

40 per 100

19 per 100
(12 to 33)

Medium risk population

41 per 100

20 per 100
(12 to 34)

Mental state: 1a. General ‐ No clinical important improvement ‐ BPRS ‐ short term

Study population

RR 0.55
(0.32 to 0.92)

28
(1 study)

⊕⊕⊝⊝
low1,5,6

917 per 1000

504 per 1000
(293 to 844)

Medium risk population

917 per 1000

504 per 1000
(293 to 844)

Mental state: 2a. Negative symptoms ‐ No clinical important improvement ‐ negative symptoms (SANS)

Study population

RR 0.76
(0.56 to 1.04)

28
(1 study)

⊕⊕⊝⊝
low1,5,6

1000 per 1000

760 per 1000
(560 to 1000)

Medium risk population

1000 per 1000

760 per 1000
(560 to 1000)

SENSITIVITY ‐ Global/mental state: No clinically important response ‐ short term

Study population

RR 0.56
(0.36 to 0.88)

221
(4 studies)

⊕⊕⊝⊝
low1,2,3,4,5,6,10

30 per 100

17 per 100
(11 to 26)

Medium risk population

31 per 100

17 per 100
(11 to 27)

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1 Unclear allocation concealment.
2 Unclear blinding or lack of blinding.
3 Incomplete outcome data not addressed in one trial.
4 Selective reporting in 2 trials.
5 Few patients.
6 Total number of events less than 300.
7 Selective reporting.
8 Large confidence interval.
9 Selective reporting in one trial.
10 Unclear blinding or lack of blinding in 3 trials.

Figuras y tablas -
Summary of findings for the main comparison. SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG compared to ANY ANTIPSYCHOTIC DRUG for schizophrenia
Ir a la tabla de la revisión
Table 1. Sulpiride reviews

Focus of review

Stage and Link

Sulpiride

Out of date full review Soares 1999

Sulpiride vs placebo

Full review Omori 2009

Sulpiride vs other antipsychotics

Protocol Omori 2009 b

Sulpiride + antidepressants

Title ‐ in preparation

Sulpiride doses

Title ‐ in preparation
Figuras y tablas -
Table 1. Sulpiride reviews
Ir a la tabla de la revisión
Comparison 1. SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs ANY ANTIPSYCHOTIC DRUG

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Global state: 1. No clinically important response Show forest plot

3

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

1.1 short term

3

193

Risk Ratio (M‐H, Fixed, 95% CI)

0.58 [0.30, 1.09]

1.2 long term ("clinical and social lack of recovery")

1

70

Risk Ratio (M‐H, Fixed, 95% CI)

0.67 [0.42, 1.08]

2 Global state: 2. Relapse Show forest plot

1

70

Risk Ratio (M‐H, Fixed, 95% CI)

0.85 [0.54, 1.33]

3 Mental state: 1a. General ‐ No clinical important improvement Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

3.1 BPRS ‐ short term

1

28

Risk Ratio (M‐H, Fixed, 95% CI)

0.55 [0.32, 0.92]

4 Mental state: 1b. General ‐ Average endpoint scores Show forest plot

1

59

Mean Difference (IV, Fixed, 95% CI)

‐3.40 [‐6.84, 0.04]

4.1 BPRS ‐ short term

1

59

Mean Difference (IV, Fixed, 95% CI)

‐3.40 [‐6.84, 0.04]

5 Mental state: 1c. General ‐ Average change in endpoint scores Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

5.1 SAPS plus SANS ‐ short term

1

70

Mean Difference (IV, Fixed, 95% CI)

‐1.74 [‐3.01, ‐0.47]

5.2 SAPS plus SANS ‐ long term

1

70

Mean Difference (IV, Fixed, 95% CI)

‐3.47 [‐4.90, ‐2.04]

6 Mental state: 1d. General ‐ Average endpoint and average change in endpoint scores (skewed data) Show forest plot

Other data

No numeric data

6.1 change in BPRS ‐ short term

Other data

No numeric data

6.2 endpoint SAPS plus SANS ‐ short term

Other data

No numeric data

6.3 endpoint SAPS plus SANS ‐ long term

Other data

No numeric data

7 Mental state: 2a. Negative symptoms ‐ No clinical important improvement Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

7.1 negative symptoms (SANS)

1

28

Risk Ratio (M‐H, Fixed, 95% CI)

0.76 [0.56, 1.04]

8 Mental state: 2b. Negative symptoms ‐ Average endpoint scores Show forest plot

1

64

Mean Difference (IV, Fixed, 95% CI)

‐6.90 [‐10.87, ‐2.93]

8.1 SANS

1

64

Mean Difference (IV, Fixed, 95% CI)

‐6.90 [‐10.87, ‐2.93]

9 Mental state: 2c. Negative symptoms ‐ Average endpoint and average change in endpoint scores (skewed data) Show forest plot

Other data

No numeric data

9.1 change in endpoint SANS ‐ short term

Other data

No numeric data

9.2 endpoint SANS ‐ short term

Other data

No numeric data

10 Mental state: 3a. Positive symptoms ‐ No clinical important improvement Show forest plot

1

28

Risk Ratio (M‐H, Fixed, 95% CI)

0.68 [0.45, 1.03]

10.1 SAPS

1

28

Risk Ratio (M‐H, Fixed, 95% CI)

0.68 [0.45, 1.03]

11 Mental state: 3b. Positive symptoms ‐ Average endpoint and average change in endpoint scores (skewed data) Show forest plot

Other data

No numeric data

11.1 change in endpoint SAPS ‐ short term

Other data

No numeric data

12 Mental state: 4. Emotional symptoms ‐ Average endpoint and average change in endpoint scores (skewed data) Show forest plot

Other data

No numeric data

12.1 depression scores (HAMD) ‐ short term

Other data

No numeric data

13 Adverse effects ‐ general: short term (skewed data) Show forest plot

Other data

No numeric data

13.1 TESS ‐ average endpoint scores (high = poor)

Other data

No numeric data

14 Adverse effects ‐ specific: 1a. CNS ‐ short term Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

14.1 dizziness

1

70

Risk Ratio (M‐H, Fixed, 95% CI)

0.63 [0.19, 2.04]

14.2 movement disorder ‐ extrapyramidal effects

1

70

Risk Ratio (M‐H, Fixed, 95% CI)

48.24 [3.05, 762.56]

14.3 movement disorder ‐ tardive dyskinesia ‐ aggravation

1

28

Risk Ratio (M‐H, Fixed, 95% CI)

2.29 [0.10, 51.85]

14.4 Drowsiness

1

70

Risk Ratio (M‐H, Fixed, 95% CI)

0.77 [0.44, 1.35]

15 Adverse effects ‐ specific: 2. Cardiovsacular system (short‐term) Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

15.1 arrythmia ‐ sinus arrythmia

1

70

Risk Ratio (M‐H, Fixed, 95% CI)

1.89 [0.18, 19.89]

15.2 ECG problems ‐ right bundle branch block

1

70

Risk Ratio (M‐H, Fixed, 95% CI)

0.32 [0.01, 7.48]

15.3 tachycardia ‐ sinus tachycardia

2

134

Risk Ratio (M‐H, Fixed, 95% CI)

1.12 [0.66, 1.88]

16 Adverse effects ‐ specific: 3a. Endocrine system (short‐term) Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

16.1 galactorrhea

1

70

Risk Ratio (M‐H, Fixed, 95% CI)

0.47 [0.04, 4.97]

16.2 weight gain

1

64

Risk Ratio (M‐H, Fixed, 95% CI)

0.3 [0.09, 0.99]

17 Adverse effects ‐ specific: 3b. Endocrine system (short‐term, skewed data) Show forest plot

Other data

No numeric data

17.1 prolactin ‐ average endpoint serum level (men)

Other data

No numeric data

17.2 prolactin ‐ average endpoint serum level (women)

Other data

No numeric data

18 Adverse effects ‐ specific: 4. Gastrointestinal system (short‐term) Show forest plot

3

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

18.1 abdominal distension

1

70

Risk Ratio (M‐H, Fixed, 95% CI)

0.10 [0.01, 0.78]

18.2 appetite ‐ loss

1

70

Risk Ratio (M‐H, Fixed, 95% CI)

0.09 [0.01, 0.70]

18.3 constipation

2

134

Risk Ratio (M‐H, Fixed, 95% CI)

0.44 [0.24, 0.81]

18.4 salavation ‐ too much

3

162

Risk Ratio (M‐H, Fixed, 95% CI)

0.49 [0.29, 0.83]

18.5 nausea

1

70

Risk Ratio (M‐H, Fixed, 95% CI)

0.06 [0.00, 0.93]

19 Adverse effects ‐ specific: 5. Haematology Show forest plot

1

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

19.1 white blood cells ‐ increase

1

70

Risk Ratio (M‐H, Fixed, 95% CI)

0.14 [0.01, 2.52]

20 SENSITIVITY ‐ Global/mental state: No clinically important response (short‐term) Show forest plot

4

221

Risk Ratio (M‐H, Fixed, 95% CI)

0.56 [0.36, 0.88]
Figuras y tablas -
Comparison 1. SULPIRIDE AUGMENTATION OF ANY ANTIPSYCHOTIC DRUG vs ANY ANTIPSYCHOTIC DRUG
Ir a la tabla de la revisión